MA35508B1 - Inhibiteurs pyrimidines de pde10 - Google Patents
Inhibiteurs pyrimidines de pde10Info
- Publication number
- MA35508B1 MA35508B1 MA6829A MA36829A MA35508B1 MA 35508 B1 MA35508 B1 MA 35508B1 MA 6829 A MA6829 A MA 6829A MA 36829 A MA36829 A MA 36829A MA 35508 B1 MA35508 B1 MA 35508B1
- Authority
- MA
- Morocco
- Prior art keywords
- pde10
- treatment
- relates
- present
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne des composés pyrimidines qui sont utiles en tant qu'agents thérapeutiques pour le traitement de troubles du système nerveux central associés à la phosphodiestérase 10 (pde10). La présente invention concerne également l'utilisation de tels composés pour le traitement de troubles neurologiques et psychiatriques, tels que la schizophrénie, la psychose ou la maladie de huntington, et ceux associés à une hypofonction striatale ou d'un dysfonctionnement des noyaux gris centraux.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161527392P | 2011-08-25 | 2011-08-25 | |
| PCT/US2012/051522 WO2013028590A1 (fr) | 2011-08-25 | 2012-08-20 | Inhibiteurs pyrimidines de pde10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA35508B1 true MA35508B1 (fr) | 2014-10-02 |
Family
ID=47746797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA6829A MA35508B1 (fr) | 2011-08-25 | 2014-03-13 | Inhibiteurs pyrimidines de pde10 |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US9062059B2 (fr) |
| EP (1) | EP2748151B1 (fr) |
| JP (1) | JP5648147B2 (fr) |
| KR (1) | KR101655635B1 (fr) |
| CN (1) | CN103917528B (fr) |
| AR (1) | AR087628A1 (fr) |
| AU (1) | AU2012299080B2 (fr) |
| BR (1) | BR112014004310B8 (fr) |
| CA (1) | CA2845578C (fr) |
| CL (1) | CL2014000450A1 (fr) |
| CO (1) | CO6890101A2 (fr) |
| CR (1) | CR20140085A (fr) |
| CY (1) | CY1117622T1 (fr) |
| DK (1) | DK2748151T3 (fr) |
| DO (1) | DOP2014000039A (fr) |
| EA (1) | EA023685B1 (fr) |
| ES (1) | ES2572527T3 (fr) |
| HK (1) | HK1193410A1 (fr) |
| HR (1) | HRP20160635T1 (fr) |
| HU (1) | HUE028451T2 (fr) |
| IL (1) | IL230997A (fr) |
| MA (1) | MA35508B1 (fr) |
| ME (1) | ME02419B (fr) |
| MX (1) | MX357241B (fr) |
| MY (1) | MY157301A (fr) |
| NI (1) | NI201400014A (fr) |
| PE (1) | PE20141535A1 (fr) |
| PL (1) | PL2748151T3 (fr) |
| RS (1) | RS54788B1 (fr) |
| SG (1) | SG2014013536A (fr) |
| SI (1) | SI2748151T1 (fr) |
| TN (1) | TN2014000070A1 (fr) |
| TW (1) | TWI450895B (fr) |
| UA (1) | UA109735C2 (fr) |
| WO (1) | WO2013028590A1 (fr) |
| ZA (1) | ZA201401272B (fr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2763533B1 (fr) | 2011-10-06 | 2021-12-29 | Merck Sharp & Dohme Corp. | Inhibiteurs triazolyles de pde10 |
| CA2851082A1 (fr) | 2011-10-06 | 2013-04-11 | Merck Sharp & Dohme Corp. | Inhibiteurs azetidines substitues en 1,3 de pde10 |
| TW201422610A (zh) | 2012-11-15 | 2014-06-16 | Merck Sharp & Dohme | 作爲ｐｄｅ１０抑制劑之經二級醇取代之三唑 |
| WO2014078217A1 (fr) * | 2012-11-15 | 2014-05-22 | Merck Sharp & Dohme Corp. | Cyclopropylimidazopyridine utilisable en tant qu'inhibiteur de pde10 |
| EP2919781B1 (fr) | 2012-11-15 | 2017-06-28 | Merck Sharp & Dohme Corp. | Cyclobutyl benzimidazoles en tant qu'inhibiteurs de pde10 |
| US9273033B2 (en) | 2012-11-20 | 2016-03-01 | Merck Sharp & Dohme Corp. | Substituted pyridone derivatives as PDE10 inhibitors |
| US9663513B2 (en) | 2012-11-20 | 2017-05-30 | Merck Sharp & Dohme Corp. | Pyrimidine PDE10 inhibitors |
| WO2014139150A1 (fr) | 2013-03-15 | 2014-09-18 | Merck Sharp & Dohme Corp. | Dérivés de pyridizinone substitués utilisés en tant qu'inhibiteurs de la pde10 |
| CU24441B1 (es) | 2014-03-24 | 2019-09-04 | Novartis Ag | Compuestos orgánicos de monobactam para el tratamiento de infecciones bacterianas |
| CN110312706B (zh) * | 2016-11-28 | 2023-08-18 | 勃林格殷格翰国际有限公司 | 茚满基氨基吡啶基环丙烷甲酸、其药物组合物及用途 |
| WO2020002314A1 (fr) | 2018-06-27 | 2020-01-02 | F. Hoffmann-La Roche Ag | Ligand du récepteur cannabinoïde 2 radiomarqué |
| AU2019294256B2 (en) | 2018-06-27 | 2024-06-20 | Eth Zuerich | Novel pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2 |
| JP2024509991A (ja) * | 2021-03-17 | 2024-03-05 | メルク・シャープ・アンド・ドーム・エルエルシー | Ｐｄｅ１０化合物のプロドラッグ |
| WO2023184486A1 (fr) * | 2022-04-01 | 2023-10-05 | Merck Sharp & Dohme Llc | Procédé de préparation de ((1s, 2s)-2-(5-méthylpyridin-2-yl)cyclopropyl)-méthanol |
| CN115403527B (zh) * | 2022-07-20 | 2024-03-29 | 西安近代化学研究所 | 一种还原胺化法合成杀菌剂乙嘧酚的方法 |
| WO2024049721A1 (fr) * | 2022-08-31 | 2024-03-07 | Merck Sharp & Dohme Llc | Administration à libération prolongée d'un inhibiteur de pde10 |
| WO2024099135A1 (fr) * | 2022-11-11 | 2024-05-16 | 杭州中美华东制药有限公司 | Inhibiteur de 1,5-naphtyridine cgas et son utilisation |
| WO2024206200A1 (fr) * | 2023-03-29 | 2024-10-03 | Merck Sharp & Dohme Llc | Formulations de pde10a à libération contrôlée |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005120514A1 (fr) | 2004-06-07 | 2005-12-22 | Pfizer Products Inc. | Inhibition de la phosphodiesterase 10 dans le traitement des etats pathologiques associes a l'obesite et au syndrome metabolique |
| JP4874983B2 (ja) | 2004-10-12 | 2012-02-15 | マックスリニアー，インコーポレイティド | デジタル発生中間周波を有する受信器アーキテクチャ |
| EP1841757B1 (fr) | 2005-01-07 | 2010-06-30 | Pfizer Products Incorporated | Composes de quinoline heteroaromatiques et leur utilisation comme inhibiteurs de pde-10 |
| GB0506883D0 (en) * | 2005-04-05 | 2005-05-11 | Astrazeneca Ab | Chemical compounds |
| ATE404554T1 (de) * | 2005-04-05 | 2008-08-15 | Astrazeneca Ab | Pyrimidinderivate zur verwendung als antikrebsmittel |
| NL2000397C2 (nl) * | 2006-01-05 | 2007-10-30 | Pfizer Prod Inc | Bicyclische heteroarylverbindingen als PDE10 inhibitoren. |
| US20090176829A1 (en) | 2006-05-02 | 2009-07-09 | Pfizer Inc | Bicyclic heteroaryl compounds as pde10 inhibitors |
| JPWO2010024258A1 (ja) * | 2008-08-29 | 2012-01-26 | 塩野義製薬株式会社 | Ｐｉ３ｋ阻害活性を有する縮環アゾール誘導体 |
| CA2736281C (fr) | 2008-09-04 | 2013-08-20 | Mitsubishi Tanabe Pharma Corporation | Pyrimidines tri-substituees et leur utilisation comme inhibiteurs de pde10 |
| ES2412780T3 (es) | 2008-09-10 | 2013-07-12 | Mitsubishi Tanabe Pharma Corporation | Compuestos aromáticos de anillo de 6 miembros que contiene nitrógeno y su uso |
| AR074343A1 (es) * | 2008-11-14 | 2011-01-12 | Amgen Inc | Derivados de piridina y pirimidina como inhibidores de la fosfodiesterasa 10 |
| MX2011006575A (es) * | 2008-12-17 | 2011-10-06 | Amgen Inc | Compuestos de aminopiridina y carboxipiridina como inhibidores de la fosfodiesterasa 10. |
| WO2011008931A2 (fr) * | 2009-07-15 | 2011-01-20 | Cystic Fibrosis Foundation Therapeutics, Inc. | Composés arylpyrimidines et thérapie de combinaison comprenant ceux-ci pour traiter une mucoviscidose et des troubles apparentés |
| TWI481607B (zh) * | 2009-12-17 | 2015-04-21 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物 |
| US8470820B2 (en) * | 2010-01-22 | 2013-06-25 | Hoffman-La Roche Inc. | Nitrogen-containing heteroaryl derivatives |
| EP2621276B1 (fr) * | 2010-09-30 | 2017-12-27 | Merck Sharp & Dohme Corp. | 2-alcoxy pyrimidine inhibiteur de pde10 |
| US8957077B2 (en) * | 2010-09-30 | 2015-02-17 | Merck Sharp & Dohme Corp. | Pyrazolopyrimidine PDE 10 inhibitors |
-
2012
- 2012-08-20 BR BR112014004310A patent/BR112014004310B8/pt active IP Right Grant
- 2012-08-20 JP JP2014527214A patent/JP5648147B2/ja active Active
- 2012-08-20 TW TW101130166A patent/TWI450895B/zh active
- 2012-08-20 HU HUE12826375A patent/HUE028451T2/en unknown
- 2012-08-20 PL PL12826375.3T patent/PL2748151T3/pl unknown
- 2012-08-20 EP EP12826375.3A patent/EP2748151B1/fr active Active
- 2012-08-20 EA EA201490492A patent/EA023685B1/ru not_active IP Right Cessation
- 2012-08-20 DK DK12826375.3T patent/DK2748151T3/en active
- 2012-08-20 ES ES12826375.3T patent/ES2572527T3/es active Active
- 2012-08-20 CN CN201280052330.4A patent/CN103917528B/zh active Active
- 2012-08-20 CA CA2845578A patent/CA2845578C/fr active Active
- 2012-08-20 SI SI201230539A patent/SI2748151T1/sl unknown
- 2012-08-20 WO PCT/US2012/051522 patent/WO2013028590A1/fr active Application Filing
- 2012-08-20 UA UAA201403008A patent/UA109735C2/ru unknown
- 2012-08-20 US US14/239,603 patent/US9062059B2/en active Active
- 2012-08-20 MX MX2014002178A patent/MX357241B/es active IP Right Grant
- 2012-08-20 KR KR1020147007427A patent/KR101655635B1/ko active IP Right Grant
- 2012-08-20 PE PE2014000255A patent/PE20141535A1/es active IP Right Grant
- 2012-08-20 RS RS20160357A patent/RS54788B1/sr unknown
- 2012-08-20 ME MEP-2016-101A patent/ME02419B/fr unknown
- 2012-08-20 AU AU2012299080A patent/AU2012299080B2/en active Active
- 2012-08-20 MY MYPI2014000504A patent/MY157301A/en unknown
- 2012-08-20 SG SG2014013536A patent/SG2014013536A/en unknown
- 2012-08-22 AR ARP120103086A patent/AR087628A1/es active IP Right Grant
-
2014
- 2014-02-16 IL IL230997A patent/IL230997A/en active IP Right Grant
- 2014-02-18 TN TNP2014000070A patent/TN2014000070A1/en unknown
- 2014-02-19 ZA ZA2014/01272A patent/ZA201401272B/en unknown
- 2014-02-24 CR CR20140085A patent/CR20140085A/es unknown
- 2014-02-24 NI NI201400014A patent/NI201400014A/es unknown
- 2014-02-25 CL CL2014000450A patent/CL2014000450A1/es unknown
- 2014-02-25 DO DO2014000039A patent/DOP2014000039A/es unknown
- 2014-02-27 CO CO14042266A patent/CO6890101A2/es unknown
- 2014-03-13 MA MA6829A patent/MA35508B1/fr unknown
- 2014-07-07 HK HK14106824.3A patent/HK1193410A1/zh unknown
-
2016
- 2016-06-08 HR HRP20160635TT patent/HRP20160635T1/hr unknown
- 2016-06-10 CY CY20161100512T patent/CY1117622T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA35508B1 (fr) | Inhibiteurs pyrimidines de pde10 | |
| WO2012044561A3 (fr) | Inhibiteurs de 2-alcoxy pyrimidine pde10 | |
| MA43169B1 (fr) | Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma | |
| MX2017011935A (es) | Compuestos de triazolil pirimidinona como inhibidores de la enzima fosfodiesterasa 2 (pde2). | |
| WO2012044562A3 (fr) | Inhibiteurs de pyrazolopyrimidine pde10 | |
| MA43756B1 (fr) | Modulateurs allostériques des récepteurs nicotiniques de l'acétylcholine | |
| WO2012054366A3 (fr) | Amino-triazolyles inhibiteurs de ped10 | |
| MA44656A (fr) | 1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones et 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones en tant qu'inhibiteurs de pde1 | |
| EA201000314A1 (ru) | 1',3'-двузамещенные-4-фенил-3,4,5,6-тетрагидро-2h,1'h-[1,4']бипиридинил-2'-оны | |
| CL2011002838A1 (es) | Compuestos derivados de 1,2,4-triazolo[4,3-a]piridina, moduladores alostéricos de receptores mglur2; composición farmacéutica; proceso para prepararla; y su uso en el tratamiento o la prevención de un trastorno del sistema nervioso central seleccionado de ansiedad y esquizofrenia, entre otros. | |
| MA35836B1 (fr) | 4 phényl-pyridines substituées pour le traitement de maladies associées à un récepteur nk-1 | |
| EA201000332A1 (ru) | 1,3-двузамещенные 4-фенил-1н-пиридин-2-оны | |
| MX2019014597A (es) | Inhibidores de pirazolopirimidina de pde9. | |
| EA201390710A1 (ru) | Производные бензодиазепина, композиции и способы для лечения когнитивного нарушения | |
| EA201991094A1 (ru) | СОЕДИНЕНИЯ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2 | |
| EA201990973A1 (ru) | СОЕДИНЕНИЯ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2 | |
| MA53351B1 (fr) | Modulateurs des récepteurs nmda hétéroaromatiques et leurs utilisations | |
| CO2023012333A2 (es) | Profármacos de compuestos de pde10 | |
| WO2014150114A8 (fr) | Dérivés de pyridizinone substitués en tant qu'inhibiteurs de pde10 | |
| MA39027A1 (fr) | Pyrido[4,3-b]pyrazine-2-carboxamides utilisées en tant qu'agents neurogènes dans le traitement des troubles neurodégénératifs | |
| ECSP14013268A (es) | Inhibidores de pde10 de pirimidina | |
| MA44503B1 (fr) | Composés de pyrrolotriazine en tant qu'inhibiteurs de tam | |
| MA45537B1 (fr) | 1h-pyrazolo [4,3-b]pyridines en tant qu'inhibiteurs de pde1 | |
| TH147865A (th) | สารยับยั้ง pde10 ประเภทไพริมิดีน | |
| EA201892113A1 (ru) | Аллостерические модуляторы никотиновых ацетилхолиновых рецепторов |